Insider Trading Activity Cancer Genetics, Inc. (NASDAQ:CGIX) – Director Bought 86,185 shares of Stock

ME Staff
-
0

Insider Trading Activity For Cancer Genetics, Inc. (NASDAQ:CGIX)

John Pappajohn , Director of Cancer Genetics, Inc. (NASDAQ:CGIX) reportedly Bought 86,185 shares of the company’s stock at an average price of 3.24 for a total transaction amount of $279,239.40 SEC Form

Insider Trading History For Cancer Genetics, Inc. (NASDAQ:CGIX)

  • On 5/21/2014 John Pappajohn, Director, bought 50,000 with an average share price of $10.31 per share and the total transaction amounting to $515,500.00.View SEC Filing
  • On 5/21/2014 Edward Sitar, CFO, bought 1,000 with an average share price of $10.67 per share and the total transaction amounting to $10,670.00.View SEC Filing
  • On 12/9/2014 John Pappajohn, Director, bought 39,686 with an average share price of $5.35 per share and the total transaction amounting to $212,320.10.View SEC Filing
  • On 12/10/2014 John Pappajohn, Director, bought 5,773 with an average share price of $5.96 per share and the total transaction amounting to $34,407.08.View SEC Filing
  • On 12/11/2014 John Pappajohn, Director, bought 27,087 with an average share price of $6.03 per share and the total transaction amounting to $163,334.61.View SEC Filing
  • On 12/15/2014 John Pappajohn, Director, bought 3,634 with an average share price of $6.14 per share and the total transaction amounting to $22,312.76.View SEC Filing
  • On 12/16/2014 John Pappajohn, Director, bought 5,589 with an average share price of $6.20 per share and the total transaction amounting to $34,651.80.View SEC Filing

    • Analyst Ratings For Cancer Genetics, Inc. (NASDAQ:CGIX)
    These are 1 Hold Rating, 3 Buy Ratings .
    The current consensus rating for Cancer Genetics, Inc. (NASDAQ:CGIX) is Buy (Score: 2.75) with a consensus target price of $6.00 , a potential (81.82% upside)

    Analyst Ratings History For Cancer Genetics, Inc. (NASDAQ:CGIX)

    • On 3/11/2016 Janney Montgomery Scott Reiterated Rating Buy to Neutral
    • On 3/15/2016 Aegis Boost Price Target of rating Buy with a price target of $8.00 to $15.00
    • On 9/26/2016 Rodman & Renshaw Initiated Coverage of rating Buy with a price target of $6.00
    • On 6/26/2017 Benchmark Co. Initiated Coverage of rating Speculative Buy with a price target of $3.85 to $6.00
    • On 6/27/2017 Dawson James Initiated Coverage of rating Buy
    • On 8/15/2017 HC Wainwright Set Price Target of rating Buy with a price target of $6.00

    Recent Trading Activity for Cancer Genetics, Inc. (NASDAQ:CGIX)
    Shares of Cancer Genetics, Inc. closed the previous trading session at 3.30 0.00 0.00% with 92,212 shares trading hands.